PATENT CLAIM ANALYSIS

Application Number: 16136065
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "108000"]

Abstract:
Oral dosage forms of osteoclast inhibitors, such as zoledronic acid, in an acid or a salt form can be used to treat or alleviate pain or related conditions, such as arthritis.

Claim (Index 24):
The method of  claim 11 , wherein the human being fasts for at least one hour prior to oral administration of the zoledronic acid and for at least one hour after oral administration of the zoledronic acid.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 97.0
- Lexical Diversity: 1.25
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15604394', '15697267', '15403073', '15439774', '15702616']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.820084792395334
- 35 USC 102 Novelty (BERT): 0.6240206222397866
- Combined Prediction Score: 0.8004783753797794
- Mean Citation Score: 609.103108
- Max Citation Score: 615.6008
- Similarity Product: 499.36485213713655

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test